Skip Navigation



JAC Advance Access published online on May 29, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg275
© 2003 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
52/1/71    most recent
dkg275v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chen, Y.-C.
Right arrow Articles by Hsieh, W.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, Y.-C.
Right arrow Articles by Hsieh, W.-C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 The British Society for Antimicrobial Chemotherapy

Original article

Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years

Yee-Chun Chen 1, Shan-Chwen Chang 1*, Kwen-Tay Luh 2, Wei-Chuan Hsieh 1

1 Department of Internal Medicine, National Taiwan University Hospital No. 7, Chung-Shan South Road, Taipei; Department of Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
2 Department of Laboratory Medicine, National Taiwan University Hospital No. 7, Chung-Shan South Road, Taipei; Department of Laboratory Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan

* Corresponding author. E-mail: sc4030{at}ha.mc.ntu.edu.tw.

Received 30 September 2002 ; revised 8 January 2003 ; accepted 2 April 2003

Abstract

The prevalence of drug-resistant bacterial pathogens is very high in Taiwan. Accordingly, there was great concern that the introduction of fluconazole would result in rapid emergence of drug-resistant yeasts. Thus, we recommended in 1991 that fluconazole be used for treatment only. To explore the impact of this policy fluconazole susceptibility of Candida species blood culture isolates and outcome of patients with nosocomial candidaemia were monitored prospectively at National Taiwan University Hospital during 1994-2000. The MICs of fluconazole were determined by the disc diffusion method. There were 1095 episodes of nosocomial candidaemia during 1994-2000. Candida albicans was the most common species (50.4%), followed by Candida tropicalis (20.5%), Candida parapsilosis (14.2%) and Candida glabrata (12.0%). There were 0-2 isolates of Candida krusei per year. The incidence of nosocomial candidaemia and the proportion of C. glabrata peaked in 1996 and decreased thereafter. Fluconazole susceptibility was determined for 552 Candida blood isolates. Only 0.7% of blood isolates were resistant to fluconazole. Fluconazole susceptibility was 94.0% in 1994-1995 and 97.9% in 1999-2000 (P = 0.06). Attributable mortality for patients with nosocomial candidaemia was 43.2% in 1994-1995 and was 25% in 2000 (P = 0.005). Despite an increase in the incidence of nosocomial fungal infection and increased consumption of fluconazole from 1994 to 2000, there was no significant change in the susceptibility to fluconazole for bloodstream isolates of Candida species. These findings appear to be attributed to several factors. These include low prevalence of C. krusei and C. glabrata, changing patterns of use of antifungal drugs and broad-spectrum antibiotics, and efforts to improve the rational use of antifungal agents at our hospital.

Keywords: Candida, nosocomial infection, antifungal susceptibility testing, outcome
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Microbiol.Home page
C.-Y. Lin, Y.-C. Chen, H.-J. Lo, K.-W. Chen, and S.-Y. Li
Assessment of Candida glabrata Strain Relatedness by Pulsed-Field Gel Electrophoresis and Multilocus Sequence Typing
J. Clin. Microbiol., August 1, 2007; 45(8): 2452 - 2459.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
M. A. Pfaller, D. J. Diekema, G. W. Procop, and M. G. Rinaldi
Multicenter Comparison of the VITEK 2 Yeast Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Fluconazole against Candida spp.
J. Clin. Microbiol., March 1, 2007; 45(3): 796 - 802.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
M. A. Pfaller and D. J. Diekema
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Clin. Microbiol. Rev., January 1, 2007; 20(1): 133 - 163.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
C. Girmenia, G. Pizzarelli, F. Cristini, F. Barchiesi, E. Spreghini, G. Scalise, and P. Martino
Candida guilliermondii Fungemia in Patients with Hematologic Malignancies.
J. Clin. Microbiol., July 1, 2006; 44(7): 2458 - 2464.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
K.-W. Chen, Y.-C. Chen, H.-J. Lo, F. C. Odds, T.-H. Wang, C.-Y. Lin, and S.-Y. Li
Multilocus Sequence Typing for Analyses of Clonality of Candida albicans Strains in Taiwan.
J. Clin. Microbiol., June 1, 2006; 44(6): 2172 - 2178.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
C.-Y. Chen, R. N. Kumar, Y.-H. Feng, C.-H. Ho, J.-Y. You, C.-C. Liao, C.-H. Tseng, P. Mavros, W. C. Gerth, and Y.-C. Chen
Treatment outcomes in patients receiving conventional amphotericin B therapy: a prospective multicentre study in Taiwan
J. Antimicrob. Chemother., June 1, 2006; 57(6): 1181 - 1188.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
M. A. Pfaller, D. J. Diekema, and D. J. Sheehan
Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing
Clin. Microbiol. Rev., April 1, 2006; 19(2): 435 - 447.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
Y. Golan, M. P. Wolf, S. G. Pauker, J. B. Wong, and S. Hadley
Empirical Anti-Candida Therapy among Selected Patients in the Intensive Care Unit: A Cost-Effectiveness Analysis
Ann Intern Med, December 20, 2005; 143(12): 857 - 869.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
M. A. Pfaller, L. Boyken, S. A. Messer, S. Tendolkar, R. J. Hollis, and D. J. Diekema
Comparison of Results of Voriconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program
J. Clin. Microbiol., October 1, 2005; 43(10): 5208 - 5213.
[Abstract] [Full Text] [PDF]

Home page
 J Med MicrobiolHome page
K.-W. Chen, H.-J. Lo, Y.-H. Lin, and S.-Y. Li
Comparison of four molecular typing methods to assess genetic relatedness of Candida albicans clinical isolates in Taiwan
J. Med. Microbiol., March 1, 2005; 54(3): 249 - 258.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P.-R. Hsueh, Y.-J. Lau, Y.-C. Chuang, J.-H. Wan, W.-K. Huang, J.-M. Shyr, J.-J. Yan, K.-W. Yu, J.-J. Wu, W.-C. Ko, et al.
Antifungal Susceptibilities of Clinical Isolates of Candida Species, Cryptococcus neoformans, and Aspergillus Species from Taiwan: Surveillance of Multicenter Antimicrobial Resistance in Taiwan Program Data from 2003
Antimicrob. Agents Chemother., February 1, 2005; 49(2): 512 - 517.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
M. A. Pfaller, A. Espinel-Ingroff, and R. N. Jones
Clinical Evaluation of the Sensititre YeastOne Colorimetric Antifungal Plate for Antifungal Susceptibility Testing of the New Triazoles Voriconazole, Posaconazole, and Ravuconazole
J. Clin. Microbiol., October 1, 2004; 42(10): 4577 - 4580.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
M. A. Pfaller, S. A. Messer, L. Boyken, S. Tendolkar, R. J. Hollis, and D. J. Diekema
Geographic Variation in the Susceptibilities of Invasive Isolates of Candida glabrata to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002
J. Clin. Microbiol., July 1, 2004; 42(7): 3142 - 3146.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.